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Osteoarthritis (OA) is a degenerative joint disease, charac-
terised by an imbalance between the synthesis and
degradation of cartilage. An enhanced breakdown of
cartilage matrix and reduced synthesis of matrix compo-
nents by articular chondrocytes eventually lead to the
destruction of the affected tissue1. The hand is a frequent
site of disease involvement in OA2. Typical joints affected
are distal interphalangeal (DIP) and proximal interphalan-
geal (PIP) joints3. Cartilage, bone and synovial alterations
in OA have been analysed in large joints such as knees and
hips, while very few data are available for hand OA.
Nevertheless, hand involvement is important as a marker
for the tendency to develop OA at other sites such as the
knee and hip4. Therefore, the availability of tests that can
detect molecular changes in cartilage homeostasis in hand
OA would be of great advantage.
The two main components of the articular cartilage matrix
are type II collagen and aggrecan, both of which are almost
tissue-speciﬁc5. Fragments produced during degradation/
synthesis of these molecules are released into biologic
ﬂuids (synovial ﬂuid, blood, urine), where they can be
measured and subsequently used as predictive markers of
disease.
Various biochemical markers have been measured in
different biological ﬂuids, predominantly in knee OA:
C-terminal crosslinking telopeptide of collagen type II
(CTX-II)6,7, and collagenase cleavage neoepitopes (Col2-
3/4Cshort, Col2-3/4Clong or C2C)8,9, markers of type II col-
lagen degradation, type II procollagen propeptides (PIICP
and PIINP)8e10, marker of type II collagen synthesis,
chondroitin sulphate (CS846 epitope)8,9, marker of pro-
teoglycan turnover.
Increased urinary6 and synovial ﬂuid7 CTX-II, increased
cartilage release of Col2-3/4Cshort and CS846 epitope8,
increased serum PIINP and urinary CTX-II10, have been
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Received 11 May 2004; revision accepted 3 June 2004.843found, revealing how in OA both synthesis and degradation
of cartilage matrix components are present.
Methods
Following this evidence, we analysed 59 patients,
diagnosed by means of clinical and radiological evaluation
as having hand OA, according to Altman et al.11. In
particular, subjects were required to have physical evidence
of hard tissue enlargement and/or deformity in three or
more index hand joints as listed in the criteria. Hand
radiographs were used to subdivide hand OA patients into
nodal and erosive. Erosive OA was deﬁned by radiographic
central erosions (‘‘gull-wing’’ erosions) and/or ankylosis in
the interphalangeal joints in at least three digits, associated
with joint-space narrowing, subchondral sclerosis and/or
osteophytes. We recruited 29 patients with nodal OA
(1 male, mean age 56.3 years ( yrs), SDG9.3, range
41e85 yrs), and 30 patients with erosive OA (4 males,
mean age 59.2 years ( yrs), SDG7.6, range 47e77 yrs).
None of the patients presented clinical manifestations of OA
in the hip or knee region. Patients with a history of other
rheumatic or skeletal degenerative diseases were excluded
from analysis. In particular, for patients with erosive OA,
subjects with psoriasis or with familial history of psoriasis
were excluded. We also analysed 21 ethnically and
geographically age-matched healthy individuals.
For each individual enrolled in the study, venous blood
was drawn for serum and plasma separation. Soon after
collection, vacutainers were centrifuged at 2000 rpm for
10 min in order to obtain serum and plasma, which were
stored at 80 (C for further analysis.
Serum concentration of 3 different markers was eval-
uated by immunoassay using a commercial enzyme-linked
immunosorbent assay (ELISA) kit (Ibex Technologies Inc.,
Montreal, Quebec), according to the manufacturer’s instruc-
tions. In particular, we analysed Col2-3/4Cshort, C2C and
CS846 epitope. The detection range is, respectively,
0.03e10 mg/mL, 3e1000 ng/mL, and 20e1000 ng/mL.
Statistical analysis was performed by KruskalleWallis
ANOVA test followed by ManneWhitney U test for unpaired
data.
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Figure 1 shows serum concentrations of these three
markers in nodal and erosive OA, and healthy controls
(CTR). Signiﬁcant differences were observed only for Col2-
3/4Cshort, since this marker’s serum concentration was
higher in both nodal and erosive OA, than in CTR (nodal vs.
CTR PZ0:005; erosive vs. CTR PZ0:0005). Erosive OA
showed a slight increase in C2C levels, and a slight
decrease in CS864 levels compared to controls, although
not signiﬁcant. No signiﬁcant differences were seen
between nodal and erosive OA.
To our knowledge, this is the ﬁrst report to analyse serum
levels of cartilage metabolism markers in hand OA.
Recently, C-telopeptide of type I collagen (CTX-I), a speciﬁc
marker sensitive to bone resorption, was evaluated in the
serum of patients with hand OA and controls12. This study
showed increased levels of CTX-I in patients with erosive
OA compared to nodal OA.
We found a signiﬁcant increase in serum levels of Col2-3/
4Cshort, a marker of cartilage catabolism, in both nodal and
erosive hand OA compared to healthy controls. From theseresults, it is not possible to speculate about what happens in
the joint compartments of OA patients, for serum levels can
be inﬂuenced by several factors. Nevertheless, some
remarks can be made.
First, these data highlight how in hand OA cartilage
metabolism is impaired, as shown by several studies
analysing knee or hip OA. Second, our data show no
signiﬁcant differences between nodal and erosive OA.
Erosive hand OA is considered by some authors as the
progression of the nodal form13, by others as a different
subset of hand OA14. We support indirectly the hypothesis
that these are not two different subsets of the hand
involvement. Third, it would be of interest to extend the
analysis of biological markers to bone and synovium as well
(i.e. pyridinoline crosslinkings, bone sialoproteins, type III
collagen) in order to have a total picture of hand joint
involvement in OA.
When analysing biological ﬂuids far from the tissue
involved (i.e. serum and urine), one should keep in mind
that type II collagen and aggrecan are also present in the
intervertebral disc, and that in adults there are variousCo
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Fig. 1. Serum levels of Col2-3/4Cshort, C2C and CS846 epitope in patients with nodal OA, erosive OA, and in healthy individuals (CTR).
Triangles show median, boxes 25th and 75th percentiles, whiskers 10th and 90th percentiles.
845Osteoarthritis and Cartilage Vol. 12, No. 10degrees of disc degeneration. Certainly, synovial ﬂuid
analysis would be more useful, but both ethically and
practically inapplicable. Furthermore, one should consider
the possibility that joint damage stimulates a systemic
increase in overall collagen metabolism. Nevertheless, the
fact that DIP and PIP joint cartilage represents only a small
fraction of total articular cartilage in the body makes it
particularly impressive that the response to this limited
damage can be detected. Thus, serum analysis can still be
useful during follow-up or to check the efﬁcacy of new
disease-modifying drugs.
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